利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.016 秒)

    C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES
    3.
    发明授权
    C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES 有权
    C2-C5-ALKYLIMIDAZOLBISPHOSPHONATE

    公开(公告)号：EP2225252B1

    公开(公告)日：2012-06-27

    申请号：EP08854485.3

    申请日：2008-11-26

    申请人： Novartis AG

    发明人： WEILER, Sven ,  WIDLER, Leo ,  RONDEAU, Jean-Michel ,  COTESTA, Simona ,  JAHNKE, Wolfgang

    IPC分类号： C07F9/6506 ,  A61K31/663 ,  A61P19/00

    CPC分类号： C07F9/65061

    摘要： C2-C5-Alkyl-substituted [(imidazol-1 -yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula (I), wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

    PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS
    7.
    发明公开
    PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS 审中-公开
    苯基 - 咪唑 - 二膦酸酯化合物

    公开(公告)号：EP2382223A1

    公开(公告)日：2011-11-02

    申请号：EP09806020.5

    申请日：2009-12-21

    申请人： Novartis AG

    发明人： COTESTA, Simona ,  JAHNKE, Wolfgang ,  RONDEAU, Jean-Michel ,  WEILER, Sven ,  WIDLER, Leo

    IPC分类号： C07F9/6506 ,  A61K31/663

    CPC分类号： C07F9/65061

    摘要： (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1- phosphono-ethyl]-phosρhonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula (I), wherein one of R
    1 and R
    2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.

    摘要翻译： （未取代的或取代的苯基） - 烷基取代的[（咪唑-1-基）-1-羟基-1-膦酰基乙基] - 膦酸，以及它们的制备方法或方法，它们在制备药物制剂中的用途 ，它们在治疗疾病中的用途，使用它们治疗疾病的方法，包含它们的药物制剂和/或用于治疗疾病的化合物。 这些化合物能够抑制过度或不适当的骨吸收。 所述化合物是式（I）的化合物，其中R 1和R 2中的一个如说明书中所定义，并且可以以游离形式，以酯和/或盐的形式存在。

    C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES
    9.
    发明公开
    C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES 有权
    C2-C5烷基咪唑双膦酸盐

    公开(公告)号：EP2225252A1

    公开(公告)日：2010-09-08

    申请号：EP08854485.3

    申请日：2008-11-26

    申请人： Novartis AG

    发明人： WEILER, Sven ,  WIDLER, Leo ,  RONDEAU, Jean-Michel ,  COTESTA, Simona ,  JAHNKE, Wolfgang

    IPC分类号： C07F9/6506 ,  A61K31/663 ,  A61P19/00

    CPC分类号： C07F9/65061

    摘要： C2-C5-Alkyl-substituted [(imidazol-1 -yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula (I), wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

    摘要翻译： C 2 -C 5 - 烷基取代的[（咪唑-1-基）-1-羟基-1-膦酰基乙基]膦酸，以及其制备方法或方法，其在制备药物制剂中的用途，它们的 用于治疗疾病，使用它们治疗疾病的方法，包含它们的药物制剂和/或用于治疗疾病的化合物。 这些化合物能够抑制过度或不适当的骨吸收，并用于治疗由靶蛋白过度异戊二烯化引起的其他疾病，如Hutchinson-Gilford早衰综合征。 所述化合物是式（I）的化合物，其中R 1和R 2中的一个是氢并且另一个是支链或非支链的C 2 -C 5 - 烷基，并且可以以酯的形式呈游离形式，和/或 的盐。